rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NEO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      NeoGenomics at Stephens conference: growth widens, margins improve
      Nov 17Investing.comNEO
      Did Narrower Quarterly Loss Just Shift NeoGenomics Stock Investment Narrative?
      Nov 6Yahoo FinanceNEO
      5 revealing analyst questions from NeoGenomics’s Q3 earnings call
      Oct 31Yahoo FinanceNEO
      NeoGenomics (NEO) Beat Q3 Expectations, Is The Stock Still Cheap?

      NeoGenomics (NEO) just delivered third quarter 2026 results that topped expectations, with double digit year over year revenue growth, improved adjusted earnings guidance, and a planned CEO transition that reshapes the leadership picture. NeoGenomics’ latest earnings surprise has arrived after a powerful run, with the share price delivering a 52.98% year to date share price return and a 75.00% total shareholder return over one year, even though the 5 year total shareholder return is still...

      Oct 29Yahoo FinanceNEO
      NeoGenomics Inc (NEO) Q3 2026 Earnings Call Highlights: Revenue Tops $209 Million as NGS Surges ...
      Oct 29Yahoo FinanceNEO
      BTIG reiterates Neogenomics stock Buy rating on strong test growth
      Oct 29Investing.comNEO
      What NeoGenomics (NEO) Said on Its Q3 Earnings Call
      Oct 29Yahoo FinanceNEO
      NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
      Oct 28Yahoo FinanceNEO
      NeoGenomics Q3 2026 slides: 53% EBITDA growth drives guidance raise
      Oct 28Investing.comNEO
      Earnings call transcript: NeoGenomics tops Q3 2026 estimates, lifts outlook
      Oct 28Investing.comNEO
      NeoGenomics Q3 2026 Earnings Call Transcript
      Oct 28BenzingaNEO
      NeoGenomics: Q3 Earnings Snapshot
      Oct 28Yahoo FinanceNEO
      NeoGenomics earnings beat by $0.02, revenue topped estimates
      Oct 28Investing.comNEO
      NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates
      Oct 28Yahoo FinanceNEO
      NeoGenomics Reports Third Quarter 2026 Results
      Oct 28Yahoo FinanceNEO
      NeoGenomics in focus: Earnings test momentum in MRD testing
      Oct 28Investing.comNEO
      Earnings to watch: NeoGenomics (NEO) reports Q3 results tomorrow
      Oct 27Yahoo FinanceNEO
      The Stock Of The Day, And Its Rivals, Are Taking A Breather

      Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.

      Oct 22Investor's Business DailyGHNEONTRA
      NeoGenomics Expands AI-Driven Digital Pathology Capabilities

      NeoGenomics (NEO) expanded its collaboration with Indica Labs to scale digital pathology operations

      Oct 15Yahoo FinanceNEO
      NeoGenomics expands Indica Labs partnership for AI pathology
      Oct 15Investing.comNEO
      Piper Sandler reiterates Neogenomics stock rating on service strength
      Oct 7Investing.comNEO
      Analysts’ Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

      Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailEQNEO
      StoneX Sticks to Their Buy Rating for NeoGenomics (NEO)

      Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailNEO
      NeoGenomics stock hits 52-week high at 20.15 USD
      Oct 7Investing.comNEO
      Why NeoGenomics (NEO) Stock Is Up Today
      Oct 6Yahoo FinanceNEO
      What's Going On With NeoGenomics Stock Tuesday? - NeoGenomics (NASDAQ:NEO)

      NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.

      Oct 6BenzingaNEO
      NeoGenomics stock down after leadership transition (NEO:NASDAQ)
      Oct 6Seeking AlphaNEO
      NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
      Oct 6Yahoo FinanceNEO
      Did Strong Q3 Outlook and New CEO Plan Just Shift NeoGenomics' (NEO) Investment Narrative?

      NeoGenomics, Inc. recently amended its bylaws to expand its Board to up to eleven directors, issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth, and outlined plans to increase full-year revenue guidance. The company also unveiled a planned leadership transition that will see President and COO Warren Stone become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the...

      Oct 6Yahoo FinanceNEO
      These Medtechs Unveiled CEO Transitions, And One Tumbled

      Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their CEOs would soon step down.

      Oct 6Investor's Business DailyNEOSYK
      Needham raises Neogenomics stock price target on revenue beat
      Oct 6Investing.comNEO
      Neogenomics stock rating upgraded at BTIG on valuation gap
      Oct 6Investing.comNEO
      Why is NeoGenomics stock sliding today?
      Oct 6Investing.comNEO
      NeoGenomics stock falls on CEO transition announcement
      Oct 6Investing.comNEO
      NeoGenomics names Warren Stone as CEO, reports Q3 revenue
      Oct 6Investing.comNEO
      NeoGenomics stock falls on CEO transition announcement

      Investing.com -- NeoGenomics Inc (NASDAQ:NEO) shares fell 3.6% in after-hours trading Monday following the company’s announcement of a CEO transition, despite preliminary third quarter revenue results that exceeded analyst expectations.

      Oct 5Yahoo FinanceNEO
      NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
      Oct 5Yahoo FinanceNEO
      NeoGenomics (NEO) Expands Precision Oncology Focus, Is The Stock Fairly Valued?

      NeoGenomics stock reaction to precision oncology expansion plan NeoGenomics (NEO) drew investor attention after executives detailed plans to expand in community-based precision oncology, highlighting next-generation sequencing, minimal residual disease testing, and workflow tools for community physicians as key focus areas. NeoGenomics shares have been on a strong run recently, with a 30-day share price return of 14.31% and a 90-day gain of 69.22%. The 1-year total shareholder return of...

      Sep 22Yahoo FinanceNEO
      Is NeoGenomics’ (NEO) Community NGS Push Quietly Redefining Its Core Earnings Engine?

      Earlier in 2026, NeoGenomics executives detailed plans to expand in community-based precision oncology, with a particular push into next-generation sequencing, minimal residual disease testing, and workflow tools for community oncologists. An important takeaway is that NGS already represents a relatively small share of test volume but a much larger portion of clinical revenue, underscoring how mix shift toward advanced assays could reshape the company’s earnings profile. We’ll now examine...

      Sep 21Yahoo FinanceNEO
      NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

      NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at t

      Sep 21Yahoo FinanceNEO
      Neogenomics stock hits 52-week high at 19.78 USD
      Sep 17Investing.comNEO
      NeoGenomics at Morgan Stanley conference: NGS, MRD drive growth
      Sep 15Investing.comNEOMS
      A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

      Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.

      Sep 11Yahoo FinanceNEO
      NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

      FORT MYERS, Fla., September 01, 2026--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

      Sep 1Yahoo FinanceNEOMS
      Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

      Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailNEOSLDB
      NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point

      NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high. Shares are up more than 170% over the past 52 weeks. NEO maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and...

      Aug 27Yahoo FinanceNEO
      NeoGenomics gains Medicare coverage for cancer MRD test
      Aug 26Investing.comNEO
      NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

      FORT MYERS, Fla., August 26, 2026--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

      Aug 26Yahoo FinanceNEO
      Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

      Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

      Aug 26Yahoo FinanceNEO
      Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and NeoGenomics (NEO)

      Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailNEOTMDX

      This is the newest page. Registered accounts read further back.